Introduction {#s1}
============

When considered separately from other cardiovascular diseases, stroke ranks fifth among all causes of death ([@B1]) and, critically, its incidence is on the rise ([@B2]).

The etiology of stroke is multifactorial with various environmental and genetic risk factors. Hypertension, diabetes and insulin resistance, smoking, dyslipidemia, obesity, heavy alcohol consumption, atrial fibrillation, and carotid stenosis are all established and well-investigated modifiable risk factors of stroke ([@B3]--[@B5]).

Additionally, there is evidence that environmental factors may also increase risk of stroke, including viral and bacterial infections, such as periodontitis ([@B6]) and respiratory infections ([@B7]), and infection with *Chlamydia pneumoniae* ([@B8]) or Cytomegalovirus ([@B9]). However, relatively little is known so far about the role of different pathogens as well as the molecular basis and the mechanisms that potentially link infections to stroke.

Here we set out to investigate whether or not infections can induce immune responses capable of cross-reacting with human proteins that, when altered, have been associated with stroke. Our hypothesis was that immune responses induced by infectious agents might cross-react with crucial stroke-related proteins, thus contributing to the multifactorial pathogenesis of cerebrovascular disease.

To address this hypothesis, we analyzed pathogens, as well as proteins that are known to be associated with increased risk of ischemic and hemorrhagic stroke by searching for common peptides that might underlie cross-reactions.

Specifically, we analyzed antigens from the following pathogens that have been reported to have a possible influence on stroke: the periodontal bacterium *Tannerella forsythia* ([@B10]), *Haemophilus influenza* ([@B11]), *Streptococcus pneumoniae* ([@B7]), *Chlamydia pneumoniae* ([@B8]), Influenza A viruses ([@B12], [@B13]), and Human Cytomegalovirus ([@B9]).

Methods {#s2}
=======

We analyzed the amino acid (aa) primary sequence of pathogen antigens (with short name and UniProt ID in parentheses): Surface antigen repeat/outer membrane protein (OMP; UniProtKB: [A0A0F7WYE8_CHLPN](A0A0F7WYE8_CHLPN)) from *Chlamydia pneumoniae*;Pneumococcal vaccine antigen A (PVAA;UniProtKB: [PVAA_STRR6](PVAA_STRR6)) from *Streptococcus pneumoniae*;Surface antigen BspA (BspA; UniProtKB: [O68831_TANFO](O68831_TANFO)) from *Tannerella forsythia*;Outer membrane antigenic lipoprotein B (LPPB; UniProtKB: [LPPB_HAEIN](LPPB_HAEIN)) from *Haemophilus influenzae* (strain ATCC 51907);Hemagglutinin (HA H1N1; UniProtKB: [HEMA_I34A1](HEMA_I34A1)) from Influenza A virus (strain A/Puerto Rico/8/1934 H1N1);Hemagglutinin (HA H5N1; UniProtKB: [HEMA_I96A0](HEMA_I96A0)) from Influenza A virus (strain A/Goose/Guangdong/1/1996 H5N1);Hemagglutinin (HA H3N2; UniProtKB: [HEMA_I68A6](HEMA_I68A6)) from Influenza A virus (strain A/Northern Territory/60/1968 H3N2); and65 kDa phosphoprotein (pp65; UniProtKB: [PP65_HCMVM](PP65_HCMVM)) from Human Cytomegalovirus (HCMV; strain Merlin).

The primary sequence of pathogen antigens was dissected into partially overlapping pentapeptides with a one-residue-offset: i.e., MFKRI, FKRIR, KRIRR, and so on. Then, each pentapeptide was analyzed for occurrences within a library consisting of primary sequences of human proteins involved in stroke. The human protein library was *a priori* chosen from the UniProtKB Database (<https://www.uniprot.org>) ([@B14]) using the keyword "stroke." We obtained an unbiased list of 74 human proteins (in)directly associated with stroke ([Table S1](#SM1){ref-type="supplementary-material"}). Stroke-related proteins are indicated as UniProtKB entry names throughout the present article, except when discussed in detail. The pathogen antigens and the human proteins were searched for common sequences using the pentapeptide as a probe unit because a pentapeptide is an immunobiological determinant sufficient for epitope-paratope interaction and for inducing specific immune responses ([@B15]--[@B18]).

The immunologic potential of the shared peptides was analyzed using the Immune Epitope Database (IEDB; [www.iedb.org](http://www.iedb.org)) ([@B19]). All evaluations were based only on epitopic sequences that had been experimentally validated as immunopositive in the human host.

This linear peptide similarity analysis procedure has been used and described before ([@B20], [@B21]).

Results {#s3}
=======

In a detailed overview, [Table 1](#T1){ref-type="table"} shows that 49 out of the 74 human stroke-related proteins share peptide sequences with antigens from pathogens that proved to be (in)directly involved in stroke ([@B6]--[@B10]). It can be seen that

-   The pathogen vs. human peptide overlap is unexpectedly high when considering that the probability for two proteins to share a pentapeptide is 1 out of 20^−5^, that is, 0.0000003125 or close to zero.

-   The peptide overlap varies widely, with *T. forsythia* BspA and Influenza A HA H3N2 being the pathogen more and less involved in the peptide sharing, respectively.

-   The high number of stroke-related proteins involved in the viral peptide overlap precludes a detailed protein-by-protein analysis. However, an example worth noting is the human ATP-binding cassette sub-family C member nine (ABCC9 or SUR2) that shares peptide sequences with all of the pathogen antigens analyzed, with the exception of the Influenza A HA H3N2 virus. ABCC9 is a subunit of ATP-sensitive potassium channels (K~ATP~) that can form cardiac and smooth muscle-type KATP channels with KCNJ11 and mediates neuroprotection ([@B22]).

###### 

Peptide sharing between pathogen antigens and human proteins that have been associated with stroke[^1^](#TN4){ref-type="table-fn"}.

  **Shared peptides[^a^](#TN1){ref-type="table-fn"}^,^[^b^](#TN2){ref-type="table-fn"}**   **Human protein involved in the peptide ^Sharing^[^b^](#TN2){ref-type="table-fn"}^,^[^c^](#TN3){ref-type="table-fn"}**
  ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  ***C. pneumoniae*** **OMP:**                                                             
  ITNYL                                                                                    **ABCC9**. ATP-binding cassette sub-family C member 9
  **RKFLL**                                                                                CCM2. Cerebral cavernous malformations 2 protein
  **RKFLL**; **KGFVS**                                                                     CCM2L. Cerebral cavernous malformations 2 protein-like
  ASSVD; LEHNQ                                                                             CSF1R. Macrophage colony-stimulating factor 1 receptor
  IALHL                                                                                    **DAPK1**. Death-associated protein kinase 1
  SEGKT                                                                                    FA5. Coagulation factor V
  PTTGI                                                                                    GNAQ. Guanine nucleotide-binding protein G(q) subunit alpha
  EGPCG                                                                                    HTRA1. Serine protease HTRA1
  NTTAE                                                                                    KCNE2. Potassium voltage-gated channel subfamily E member 2
  GFRCL; LRSSA                                                                             NOTC3. Neurogenic locus notch homolog protein 3
  VSAAG                                                                                    **NU155**. Nuclear pore complex protein Nup155
  SGLGG                                                                                    PAWR. PRKC apoptosis WT1 regulator protein
  SGNQV                                                                                    PDE4D. cAMP-specific 3′,5′-cyclic phosphodiesterase 4D
  GYFAS                                                                                    **RN213**. E3 ubiquitin-protein ligase RNF213
  DSPRT; SPRTP                                                                             SAMH1. Deoxynucleoside triphosphate triphosphohydrolase SAMHD1
  ***S. pneumoniae*** **PVAA:**                                                            
  LAMIY                                                                                    **ABCC9**. ATP-binding cassette sub-family C member 9
  TVAPL; VAPLL                                                                             KCNA5. Potassium voltage-gated channel subfamily A member 5
  AQNGK                                                                                    KLOT. Klotho
  SASGS                                                                                    LMNA. Prelamin-A/C
  LVLAV                                                                                    NMDE2. Glutamate receptor ionotropic, NMDA 2B
  IQTLT                                                                                    NU5M. NADH-ubiquinone oxidoreductase chain 5
  ***T. forsythia*** **BspA:**                                                             
  AWTAR; SGTKT                                                                             A4. Amyloid-beta A4 protein
  GLTTI; LTITN                                                                             **ABCC9**. ATP-binding cassette sub-family C member 9
  TLSAL                                                                                    BI1. Bax inhibitor 1
  APGRA                                                                                    CO4A2. Collagen alpha-2(IV) chain
  GKKAV                                                                                    COQ8A. Atypical kinase COQ8A, mitochondrial
  IIFVS                                                                                    CXA5. Gap junction alpha-5 protein
  NCGAL                                                                                    GATA5. Transcription factor GATA-5
  HSLQS                                                                                    GATA6. Transcription factor GATA-6
  LGATA; GATAQ                                                                             IL4. Interleukin-4
  DALTT                                                                                    ITIH4. Inter-alpha-trypsin inhibitor heavy chain H4
  AGGAL; VTTIG                                                                             KCNQ1. Potassium voltage-gated channel subfamily KQT member 1
  TAPDA                                                                                    KRIT1. Krev interaction trapped protein 1
  EGFAL                                                                                    LYAM3. P-selectin
  VTQNP                                                                                    NMDE2. Glutamate receptor ionotropic, NMDA 2B
  DGVNT; SGTTG                                                                             NOTC3. Neurogenic locus notch homolog protein 3
  GLFLL                                                                                    SCN4B. Sodium channel subunit beta-4
  TLPNS                                                                                    SCN5A. Sodium channel protein type 5 subunit alpha
  TLPDG; VTLPN                                                                             SYLM. Probable leucine---tRNA ligase, mitochondrial
  LPDAL; LTLSA; SGLTS; TLPDA                                                               **ZFHX3**. Zinc finger homeobox protein 3
  ***H. influenzae*** **LPPB:**                                                            
  TSNFP; GIDIS                                                                             ABCC9. ATP-binding cassette sub-family C member 9
  LLLPL                                                                                    ACE. Angiotensin-converting enzyme
  SFLLL; TTTVS                                                                             ANF. Natriuretic peptides A
  AQPAF                                                                                    CSF1R. Macrophage colony-stimulating factor 1 receptor
  ILVAD                                                                                    ENPP4. Bis(5′-adenosyl)-triphosphatase ENPP4
  **VTSSV**                                                                                GATA6. Transcription factor GATA-6
  GNLII                                                                                    ITIH4. Inter-alpha-trypsin inhibitor heavy chain H4
  PGANG; SGSRG                                                                             KCNA5. Potassium voltage-gated channel subfamily A member 5
  APDYS; PDYSK; DYSKI; TYTPG                                                               KRIT1. Krev interaction trapped protein 1
  SNVGG; SPSVP                                                                             NU155. Nuclear pore complex protein Nup155
  **AYLAG**                                                                                PDE3A. cGMP-inhibited 3′,5′-cyclic phosphodiesterase A
  LLPLS;**AYLAG**; **VTSSV**; QEVKA                                                        RN213. E3 ubiquitin-protein ligase RNF213
  GPIKS                                                                                    SCN5A. Sodium channel protein type 5 subunit alpha
  KKSFL                                                                                    SYLM. Probable leucine--tRNA ligase, mitochondrial
  **Influenza A HA H1N1:**                                                                 
  DGVKL                                                                                    ADA2. Adenosine deaminase 2
  LLVSL                                                                                    ATP6. ATP synthase subunit a
  ENAYV                                                                                    **ABCC9**. ATP-binding cassette sub-family C member 9
  ASSLV                                                                                    PDE3A. cGMP-inhibited 3′,5′-cyclic phosphodiesterase A
  **AELLV**; **ELLVL**; LLVLL; LVLLV                                                       **DAPK1**. Death-associated protein kinase 1
  TVLEK; YVSVV; QTPLG; FLDIW                                                               **RN213**. E3 ubiquitin-protein ligase RNF213
  TSNAS                                                                                    NMDE2. Glutamate receptor ionotropic, NMDA 2B
  CALAA                                                                                    GAS6. Growth arrest-specific protein 6
  LLVLL;YAADQ; KVDGV                                                                       KLOT. Klotho
  EELRE                                                                                    LMNA. Prelamin-A/C
  YSEES                                                                                    **ZFHX3**. Zinc finger homeobox protein 3
  **Influenza A HA H5N1:**                                                                 
  LLAIV                                                                                    AL5AP. Arachidonate 5-lipoxygenase-activating protein
  **LLLAI**                                                                                **ABCC9**. ATP-binding cassette sub-family C member 9
  AQDIL; ISGVK                                                                             PDE4D. cAMP-specific 3′,5′-cyclic phosphodiesterase 4D
  **LLLAI**                                                                                CYTC. Cystatin-C
  QRLVP; **AELLV**; **ELLVL**                                                              **DAPK1**. Death-associated protein kinase 1
  ILEKT; LKHLL; **VSSAC**                                                                  **RN213**. E3 ubiquitin-protein ligase RNF213
  EGGWQ                                                                                    KLOT. Klotho
  **SLALA**                                                                                NU5M. NADH-ubiquinone oxidoreductase chain 5
  KIVLL; LVLAT                                                                             **NU155**. Nuclear pore complex protein Nup155
  ARLNR; SIYST                                                                             KCNQ1. Potassium voltage-gated channel subfamily KQT member 1
  **VSSAC**                                                                                SCN1B. Sodium channel subunit beta-1
  VPEWS                                                                                    TBX5. T-box transcription factor TBX5
  SVAGW                                                                                    S19A2. Thiamine transporter 1
  **SLALA**                                                                                GATA5. Transcription factor GATA-5
  **Influenza A HA H3N2:**                                                                 
  GGSNA; **AELLV**                                                                         **DAPK1**. Death-associated protein kinase 1
  INSNG                                                                                    SAMH1. Deoxynucleoside triphosphate triphosphohydrolase SAMHD1
  KITYG                                                                                    MYL4. Myosin light chain 4
  LLGDP                                                                                    KCNA5. Potassium voltage-gated channel subfamily A member 5
  ISFAI                                                                                    HTRA1. Serine protease HTRA1
  VLNVT                                                                                    SCN3B. Sodium channel subunit beta-3

*References in [Table S1](#SM1){ref-type="supplementary-material"} (Supplementary Material)*.

*Viral/bacterial antigens are described under Methods. Further details at <https://www.uniprot.org> ([@B14])*.

*Multiple occurrences in bold*.

*Human proteins given as UniProt entry and name. Further details at <https://www.uniprot.org> ([@B14])*.

In summary, [Table 1](#T1){ref-type="table"} describes a peptide platform that connects the infectious agents under analysis human proteins related to stroke.

Subsequently, in order to define the immunologic potential of the shared peptides, we conducted analyses throughout the peptide immunome cataloged in the Immune Epitope Database (IEDB; [www.iedb.org](http://www.iedb.org)) ([@B19]). The search was finalized to identify epitopic sequences corresponding to (or containing) the peptide sequences shared between stroke-related infectious agents and stroke-related human proteins. It was found that a great number of the shared peptides listed in [Table 1](#T1){ref-type="table"} are also distributed through hundreds of epitopic sequences with an immunological potential. A list of such epitopic sequences is reported in [Table 2](#T2){ref-type="table"}.

###### 

Epitopes immunopositive in the human host and containing peptide sequences common to antigens from stroke-related pathogens and human proteins associated with stroke.

  **1**    **2**             **1**    **2**              **1**    **2**             **1**    **2**
  -------- ----------------- -------- ------------------ -------- ----------------- -------- -------------------
  58129    SGLTSlf           459109   sLLPLShlv          554097   lvesyTLPDGrii     634993   mplhVAPLLaa
  66225    tSGLTSl           466105   gtdpLVLAV          554098   lvesyTLPDGriikv   637221   slsdLLVSL
  66817    ttSGLTS           467909   LLLPLnlev          554195   mfehlINSNGikpv    638032   tpLLLPLaa
  69631    vLLVSLgai         471133   SPRTPppltv         555093   qgDGVKLhlkakaev   638320   vhEGPCGisy
  79809    ELLVLLenertld     471667   tlAELLVLL          555672   rlsrlqekEELRE     642301   eqklnrypASSLVvvr
  113324   dgFLDIWtynAELLV   475091   aekeNTTAEl         557456   vlvesyTLPDGrii    642391   etpvyLGATAgmrll
  113533   idlwsynAELLVal    476155   ASSLVdtpk          559587   gnENAYVkngklhls   644577   iekdlilLGATAvedrl
  143137   tSASGSgedaidesg   476488   avdDGVNTf          563134   evAELLVkh         644669   iifgASSVDf
  150977   eeaklnreeiDGVKL   478710   GLTTIlknv          570114   AELLVshga         645002   inhvvSVAGWgisd
  151075   ynAELLVLLenertl   482488   neILVADty          571918   EELRElaesw        645986   kpTLSALpsplvtsg
  151076   ypgdfidyEELREql   482780   nrypASSLV          573110   haCALAAslw        648442   qgkdlqqYVSVVvld
  163409   setdaLRSSA        482921   pkyvksnrLVLATg     574223   kpagpLGATA        649953   sldrSLALAaeep
  164690   fLLVLLdyqgmlp     483957   reSNVGGiqql        575691   nrypASSLVvv       691126   klnrypASSLVvvr
  164772   gvdtGIDIShsdf     485150   rySGNQVlf          577376   rVLNVTnlef        691145   kpTLSALpsplvts
  178609   avvvlkrLPDALadg   485418   sedpsGKKAVl        577393   rvqGYFASf         691655   neqklnrypASSLVv
  182409   stvASSLVLLVSLga   487836   TVLEKfrylpk        578014   SPRTPnrsv         692295   skpTLSALpsplvtsg
  182414   yqilaiystvASSLV   488193   vifftSGTTGfpk      578015   SPRTPsntp         694354   eskrKKSFLlcig
  184585   lrTTTVSgkl        488539   vVAPLLrkv          578016   SPRTPsntpsa       695746   pltspttsqLRSSAp
  190442   hELLVLvkkaq       488926   ypASSLVvv          578044   SPSVPktsa         695843   pSASGSsgntptppn
  194133   llaAWTARa         489284   LLLPLpvpa          579718   vyLKHLLpk         695894   pttsqLRSSApshaq
  196781   sILEKTsay         490154   araLLLPLl          581635   aeLLLPLkvl        696039   qLRSSApshaqtpwp
  213534   kssSGTKTtk        492412   irfgLLPLSm         581817   anatLLPLSl        699244   aqhSGLGGvshy
  223189   ldLLLPLnl         492430   irfSGTTGqm         582446   eeLLLPLly         699571   asiVAPLLl
  223510   pelLLLPL          492987   lepcsrlLLLPLl      583971   iamhaaLLLAI       699594   aslVAPLLi
  223880   seeLLLPLl         493322   mpepasrclLLLPL     584143   ildksVAPLL        699595   aslVAPLLl
  226701   yvftLLVSL         493610   plLLVSLw           584764   kgVSAAGilek       700497   deVTLPNvv
  240338   sASSLVnldslv      493947   qrqqLLVSL          584945   klrEELREk         700729   difqQTPLGr
  243935   FLDIWtyna         495137   srlLLLPLl          587249   prclLLVLL         700885   dpSGTKTcidtkeg
  419699   gpprlLLLPL        495478   traLLLPLl          587956   raqggLLVLL        702273   EELREkyrry
  423950   alLKHLLsy         496437   eirTVLEKl          589061   rrgELLVLr         702274   EELRElanky
  424543   fLLPLSlif         497010   tpvyLGATAgmrll     590120   srsKIVLLv         703553   erySGNQVl
  426499   nfkAWTARy         504703   clyvLLLAI          590169   stsSPSVPk         704661   evvtSEGKTk
  430136   fspdLLGDPdny      505049   elitILEKT          590856   vpglcllvll        705071   fAQPAFml
  430260   fTVLEKfry         505187   fasVAPLLef         590986   vsgTLPDGhmp       706516   fsLLPLShl
  435575   rrlLLLPLl         505268   flaptfSGLTSi       592071   dttyinhvvSVAGWg   710491   ieILEKTttiy
  435576   rrlLLLPLll        507273   mpllLLLPL          594553   atiEELRErvw       711114   ipingSPRTPr
  436423   apfGPIKSidm       507346   mtlLLLPL           595684   gLLAIVkv          711645   itnvAELLV
  437494   gAGGALfvhrd       507484   palSPSVPl          600696   qttTVLEKy         712552   kfpeiVAPLL
  437792   gSGLGGltdk        510341   ypASSLVv           601366   rTLPDGthel        713254   klkikelre
  440682   SPRTPvspvkf       511858   ardSLALArpkssdvy   601983   sryLLPLSalgtvag   713313   kLLLAIktk
  441210   TVLEKvyel         518869   inhvvSVAGWgisdg    602564   tiEELRErvw        716976   ltneKIVLL
  442404   apaAPGRAl         519272   itILEKTvspdrle     610338   QEVKAitkl         720288   qhyelcSGNQV
  443560   erySGNQVlf        520276   kqqeLLVSL          611939   rrvkAELLV         721762   rgaLLPLSi
  444320   glsLLPLSek        521984   lrqaAGGALqvvhsr    614291   asfapISFAIk       722338   rlLLLPLl
  445722   kpkhPTTGI         523925   qaAGGALqvvhsrql    615815   evAELLVrh         722416   rlprLLVLL
  448068   rvrvPTTGI         532960   mPTTGIney          616957   glvnSGLTSv        723746   rvpaLLVLL
  448661   SPRTPpqrf         535612   ELLVLrqkhsepsrf    620774   kvleAELLVLr       723778   rvpsLLVLL
  448662   SPRTPtpfkhal      537116   nkvleAELLVLrqkh    623038   qrAGGALsi         724649   SEGKTfqly
  448918   sryLLPLSa         541075   allpAGGALqh        627837   vPTTGIiey         724650   SEGKTkpli
  449866   VSAAGlvqgl        541668   eEELREkqay         628836   AELLVkgyei        725019   sgdGPIKSv
  453784   flplLLVLL         541699   EELREkqay          628959   ailhLLVSL         725662   slVAPLLi
  456288   LLLAIiphv         544699   rggaAGGALp         630008   dvAGGALthsll      727559   TAPDAaltl
  456316   LLLPLplll         545442   srvpLLLPL          632600   iLLLPLhtg         728413   TLPDGthel
  457304   ntlLLVSL          548131   hLLGDPmanv         633968   lLLLPLpvpa        728445   TLSALyarr
  457363   pekTLSALl         551494   esyTLPDGrii        634370   lprLLVLLa         729508   tvpdLLLPL
  458091   rlAELLVsv         553367   kpvlqkyAELLV       634991   mplhVAPLL         732341   yAPDYSsrl

*Column 1: Epitopes listed according to the IEDB-ID number. Epitope details and references at [www.immuneepitope.org](http://www.immuneepitope.org) ([@B19]). Column 2: Sequences common to pathogen antigens and human proteins related to stroke are indicated in capital letters*.

Conclusion {#s4}
==========

Stroke risk appears to be the result of a complex combination of multiple genetic non-modifiable and environmental modifiable factors that can be further classified as either "traditional" or new, "emerging" ones ([@B23]). As highlighted by Grau et al. ([@B24], [@B25]), the occurrence of stroke is only partially explained by traditional modifiable cardiovascular risk factors, such as increasing blood pressure, cigarette smoking, and diabetes mellitus. Most importantly, infectious diseases appear to play a key role in contributing to the risk of stroke and are to be counted among "emerging" modifiable risk factors that receive increasing scientific interest ([@B6]--[@B10], [@B23], [@B26], [@B27]).

Searching for possible immunopathogenic links between infection and risk of stroke, the present study aimed to analyze the potential immunologic relationship between pathogens and human proteins that, when altered, have been associated with risk of stroke. In line with our hypothesis, we found that immune cross-reactions between infectious pathogens and human stroke-related proteins might occur, thus increasing the risk of stroke (see [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}).

The immunologically relevant peptide sharing reported in the present study depicts a complex scenario. Some potential molecular targets of cross-reactions are proteins belonging to the cardiovascular system, thus possibly directly accounting for cerebrovascular damage. Other possible targets are proteins of the immune system, thus suggesting mechanisms resulting in immune dysregulation which could lead to cerebrovascular damage.

An example of the first type of potential targets are ion-channels, particularly potassium (K^+^) and sodium (Na^+^) channels (ABCC9, KCNE2, KCNA5, KCNQ1, SCN4B, SCN5A, SCN1B, SCN3B, see [Table 1](#T1){ref-type="table"}). Accordingly, a growing body of evidence points to the involvement of cardiac K^+^ and Na^+^ channel dysfunction (cardiac channelopathies as a result of genetic mutations and/or inflammatory mechanisms) in the pathogenesis of atrial fibrillation (AF), an established risk factor for stroke ([@B28], [@B29]). Moreover, autoantibodies targeting ion-channels may be involved in cardiac arrhythmias ([@B30]). In light of the potential cross-reactivity suggested by the observed peptide sharing, AF and subsequent stroke could result from antibodies primarily targeting epitopes of infective agents but also cross-reacting with cardiac ion channels. For instance, activating antibodies could lead to a gain-of-function of K^+^-channels and inhibiting antibodies to a loss-of-function of of Na^+^-channels. This could promote re-entry or increase susceptibility to early and/or delayed afterdepolarizations, two mechanisms that can generate AF ([@B31], [@B32]).

The second class of potential targets includes proteins that actively modulate the inflammatory response, such as cytokines and colony-stimulating factor receptors (IL-4, macrophage colony-stimulating factor 1 receptor, see [Table 1](#T1){ref-type="table"}) ([@B33], [@B34]). IL-4, for example, is a well-investigated tolerogenic cytokine that is able to suppress inflammatory responses and organ-specific autoimmunity in both animal models and humans ([@B35], [@B36]). It is then conceivable that autoantibodies downregulating the function of these proteins can promote inflammatory responses, thus increasing the risk of cerebrovascular damage and stroke. Indeed, inflammatory responses appear to be crucial in the pathogenesis of stroke by inducing atherosclerosis progression, pro-thrombotic activation, and AF---among other mechanisms ([@B37]). Inflammation can therefore be considered as one key factor underpinning the relationship between classical stroke risk factors and comorbidities. It appears that not just single infections, but overall infectious burden from multiple agents predicts stroke incidence. Moreover, poor outcome may be proportional to systemic inflammatory burden both in patients and experimental models. For instance, Influenza and Streptococcus infection seem to contribute to stroke incidence and outcome, and evidence from experimental models indicate that blocking inflammatory processes might be an effective prevention strategy ([@B38], [@B39]).

The increasingly recognized relevance of inflammation in stroke is consistent with a possible role of peptide sharing-based cross-reactivity as contributing factors to cerebrovascular damage. In fact, the past two decades of immunologic research have radically changed the way we think of inflammation and innate immunity. It is now known that innate immune responses can "specifically" drive the following adaptive responses through recognition of pathogen-associated molecular patterns (PAMPs) ([@B40], [@B41]). That is to say that peptide epitopes, cell-wall components, and other PAMPs activate immune cells already from the very first stages of immune reactions and drive inflammation. Indeed, there are examples of cross-reactivity between host and pathogen-associated molecular patterns: identical inflammasomes and toll-like receptors (TLRs) recognizing molecular fingerprints of both pathogens (the PAMPs) and injured host cells (so-called danger-associated molecular patterns; DAMPs). For instance, both bacteria LPS and HMGB1 from injured host cells activate TLR4, with consequent inflammation in various tissues including the brain ([@B41], [@B42]). TLR- and inflammasome-dependent pathways seem to be important drivers of inflammation, vascular disease, and reportedly contribute to stroke outcome ([@B43], [@B44]).

Our preliminary results underline the importance of further experimental efforts to define the molecular basis through which microbial infections might contribute to an increased risk of stroke ([@B45]--[@B50]). Future studies should evaluate immunoreactivity against the peptides shared by infectious pathogens and human stroke-related proteins in sera from stroke patients. Possibly, such serological analyses could also help identify specific markers predicting a higher risk of stroke and might therefore be useful to design preventive strategies following an infection. The ultimate translational relevance of our finding lies in the possibility of adopting effective individualized primary and secondary preventive strategies in patients at risk for stroke after infections. Generic hygienic measure, as well as antibiotic prophylaxis and vaccination campaigns have already been proposed and tested with contrasting results ([@B37]). Identifying and stratifying patients according to individual biomarker profiles would allow to personalize treatment for each patient, thus possibly increasing overall efficacy.

Until now, stroke is a leading cause of preventable death and adult disability ([@B1]--[@B5], [@B47]--[@B52]), but preventive strategies mostly concentrate on traditional cardiovascular risk factors ([@B53]--[@B56]). Moreover, "cryptogenic" stroke (i.e., ischemic stroke with no obvious cause) poses a challenge in terms of primary and secondary prevention ([@B57], [@B58]).

Given the burden of cerebrovascular disease, and the potential to identify immunological markers that may then serve as prognostic indicators of risk of cerebrovascular damage after an infection, our results justify further intensive research on the cross-reactive link between infections and risk of stroke.
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